Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955213 | 0.78 | AGBL2 (0.35) | — | |
| SCHEMBL3576871 | 0.78 | AGBL2 (0.35) | — | |
| SCHEMBL29956920 | 0.77 | — | — | |
| SCHEMBL22026605 | 0.77 | — | — | |
| SCHEMBL114902 | 0.77 | CCR1 (0.35) | PLAUNPC1 | |
| SCHEMBL29925415 | 0.77 | CCR1 (0.35) | PLAUNPC1 | |
| SCHEMBL115615 | 0.75 | PLAU (0.32) | HTTKMT2AHSD17B10SMN1; SMN2PLAU | |
| SCHEMBL28346880 | 0.75 | KMT2A (0.54) | HTTKMT2AHSD17B10SMN1; SMN2PLAU | |
| SCHEMBL1136919 | 0.72 | OPRK1 (0.34) | HTTKMT2ANPC1ALDH1A1OPRK1 | |
| SCHEMBL116093 | 0.72 | ENPP2 (0.36) | NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112086564-A | Passivating agent and passivation method thereof and method for preparing semiconductor film | 杭州纤纳光电科技有限公司 | 2020-12-15 | — | — | CN | claimed |
| CN-111435705-A | Repairing agent and repairing method thereof and method for preparing photoelectric film | 杭州纤纳光电科技有限公司 | 2020-07-21 | — | — | CN | claimed |
| EP-4667464-A1 | AZOLYLPYRIDINE PYRIDAZINONE AMIDE AS SOS1 INHIBITOR | Cyrus Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024259328-A1 | INHIBITORS OF RIPK2 AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024172632-A1 | AZOLYLPYRIDINE PYRIDAZINONE AMIDE AS SOS1 INHIBITOR | (주) 사이러스테라퓨틱스 | 2024-08-22 | — | — | WO | disclosed |
| US-RE49735-E1 | Oxazolidinones as modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-28 | — | — | US | disclosed |
| CN-111435705-B | Repairing agent and repairing method thereof and method for preparing photoelectric film | 杭州纤纳光电科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-108699065-B | Tricyclic compounds and compositions as kinase inhibitors | 诺华股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| EP-3390404-B1 | TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-10968203-B2 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders | GENENTECH, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| CN-112086564-A | Passivating agent and passivation method thereof and method for preparing semiconductor film | 杭州纤纳光电科技有限公司 | 2020-12-15 | — | — | CN | disclosed |
| WO-2009151598-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009151598-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
| US-20090099217-A1 | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies | ASTEX THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| WO-2009032249-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK & CO., INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| EP-2004630-A1 | 2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR TREATING OR PREVENTING A -RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2008-12-24 | — | — | EP | disclosed |
| US-20080293768-A1 | Novel Compounds Derived From 5-Thioxylose And Their Use In Therapeutics | INVENTIVA (FR) | 2008-11-27 | — | — | US | disclosed |
| WO-2007114771-A1 | 2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR TREATING OR PREVENTING Aβ-RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
| US-20070185125-A1 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293768-A1 | Novel Compounds Derived From 5-Thioxylose And Their Use In Therapeutics | TPMT, STS, TBXAS1 | HTT 1773/4885KMT2A 4478/4885HSD17B10 892/4885 |
| US-20090099217-A1 | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies | PSEN2, APP, PSEN1 | HTT 55/4885KMT2A 1048/4885HSD17B10 1400/4885 |
| US-20070185125-A1 | Pyridones useful as inhibitors of kinases | MAP3K20, MAP3K6, MAP3K5 | HTT 2407/4885KMT2A 1392/4885HSD17B10 2860/4885 |
| US-10968203-B2 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders | XBP1, ERN1, ATF4 | HTT 3388/4885KMT2A 4455/4885HSD17B10 2051/4885 |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A2, GUCY1A1 | HTT 2835/4885KMT2A 4012/4885HSD17B10 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.